Neuropsychological Studies of Children With Sickle Cell

NCT ID: NCT00005438

Last Updated: 2016-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

1993-02-28

Study Completion Date

1998-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To identify those factors that contributed to cognitive deficiencies in children with sickle cell disease (SCD) who had not demonstrated any overt or clinically apparent neurological abnormalities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

Although there has been evidence for a relationship between sickle cell disease and pathology of the central nervous system since 1923, there has been a tendency in the psychosocial literature to attribute any decreased cognitive performance in children with sickle cell disease to illness-related or demographic factors (e.g., school absenteeism, socioeconomic status) rather than to the disease process of SCD (e.g., chronic microvascular insults to the central nervous system). Cerebral infarction is the most common neurological complication that occurs in children with SCD, but clinically it presents itself in only five to ten percent of children with this chronic illness. The majority of children with SCD are also at high risk of demonstrating learning deficits and poor school performance. Studies suggest that a significant number of children with SCD who do not display any overt symptomatology of neurologic disease often exhibit decreased academic performance in comparison to healthy matched peers. Given the pathophysiology of SCD, it is reasonable to hypothesize that the insidious onset of impaired cognitive functioning is the result of multiple microinfarcts, small hemorrhages, and progressive vascular disease. Therefore, the disease process of SCD could be a primary contributing factor to long-term decreased cognitive performance often demonstrated by the adult SCD population. It is thus critical to examine young children with SCD who do not exhibit gross manifestations of neurological insult in order to determine the cause of these cognitive deficits.

DESIGN NARRATIVE:

A total of 60 infants and toddlers with SCD and 60 matched normally-developing peers between the ages of birth and three years served as subjects in a five-year longitudinal design in order to permit between-group comparisons. Subjects were assessed at regularly scheduled intervals with a variety of developmental (e.g., Bayley), cognitive (e.g., Stanford-Binet), neuropsychological (e.g., Purdue Pegboard), family functioning, and physiological indices in order to delineate those factors in the SCD group that were associated with decreased cognitive and academic performance. A unique and important feature of this research was the inclusion of magnetic resonance imaging technology. These techniques made it possible to study in a comprehensive and componential manner the neuroanatomical effects of SCD instead of relying on any single instrument or assessment to document this phenomenon. Goals of this study included the identification of: (a) specific areas of learning deficiencies in children with SCD; (b) the period in which these deficiencies began to occur; and (c) the relationship between types of learning deficits and various outcome measures. In sum, this study helped to determine how these factors interacted and changed over time as the child with SCD matured, the disease fluctuated, and the family and/or the environmental context changed in relation to cognitive development.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Disease Anemia, Sickle Cell Neurologic Manifestations

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

No eligibility criteria
Maximum Eligible Age

100 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role lead

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R29HL047872

Identifier Type: NIH

Identifier Source: secondary_id

View Link

4366

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.